Drugs in the Pipeline
The FDA has granted Priority Review to dapagliflozin (Farxiga) for the treatment of new or worsening CKD.
Drugs in the Pipeline
The multicenter, event-driven, double-blind, placebo-controlled trial compared the effect of dapagliflozin to placebo on renal outcomes and cardiovascular mortality in patients with CKD.
Drugs in the Pipeline
The designation was granted based on results from the phase 3 DAPA-CKD trial, which was stopped early due to “overwhelming efficacy”.
Clinical Charts
FDA-approved antiviral therapies for the treatment and prophylaxis of influenza.
SABCS 2021
Elacestrant showed a statistically significant and clinically meaningful progression-free survival improvement compared with standard of care.
Clinical Charts
Antidiabetic agents for the treatment of diabetes including maintenance and max doses.
Clinical Charts
Drug therapy for the treatment of irritable bowel syndrome (IBS).
SABCS 2021
Monitoring bESR1mut enabled optimization of the endocrine therapy used with a CDK4/6 inhibitor.
Clinical Charts
Parkinson's drug treatment chart categorized by pharmacological class.
Clinical Charts
FDA-approved drug therapies for cutaneous melanoma.